SNSE
- Sensei Biotherapeutics, Inc.
()
Overview
Company Summary
Sensei Biotherapeutics, Inc. is a biotechnology company that specializes in the development of personalized medicines for the treatment of cancer. The company focuses on developing targeted immunotherapies that stimulate and enhance a patient's own immune system to effectively fight cancer cells.
Sensei Biotherapeutics utilizes its proprietary ImmunoPhage� platform, which is a combination of phage display technology and next-generation sequencing, to identify and design novel immunotherapies. This platform allows the company to identify specific antigens present on cancer cells that can be targeted by the immune system.
The company's lead product candidate is called SNS-301, which is a potential treatment for head and neck squamous cell carcinoma (HNSCC) and other solid tumors. SNS-301 is a fusion protein designed to elicit a potent immune response against the tumor cells that express a particular antigen known as Aspartyl-beta Hydroxylase (ASPH).
In addition to SNS-301, Sensei Biotherapeutics is also developing several other product candidates using its ImmunoPhage� platform. These include SNS-401, which targets acute myeloid leukemia (AML), and SNS-301-NG, which is an enhanced version of SNS-301 with improved immunogenicity.
Sensei Biotherapeutics collaborates with academic institutions, clinical centers, and pharmaceutical companies to advance its research and development efforts. The company's mission is to transform the treatment of cancer by harnessing the power of the immune system and developing personalized therapies that offer better outcomes for patients.